Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Outlook

Thelansis’s “Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Overview

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a neuropathic condition affecting peripheral nerves and nerve roots. It is acquired and mediated by the immune system, typically presenting with recurring or progressively worsening symmetrical weakness in both proximal and distal muscle groups. Clinically, CIDP is divided into two categories: “typical” and “atypical” cases. Typical CIDP manifests as a symmetrical polyneuropathy, equally impacting both proximal and distal muscles. In contrast, atypical CIDP includes conditions like ‘distal acquired demyelinating symmetric’ (DADS) and multifocal acquired demyelinating sensory and motor neuropathy (MADSAM), also known as Lewis-Sumner syndrome (LSS). DADS is characterized by a symmetrical, length-dependent sensory or sensorimotor neuropathy, often associated with an IgM paraprotein and significantly increased distal motor latencies. While these features resemble demyelinating neuropathy with antibodies against myelin-associated glycoprotein (MAG), anti-MAG neuropathy is excluded from CIDP according to EFNS/PNS criteria due to the presence of specific antibody presence and distinct treatment responses. LSS exhibits a multifocal distribution; a key electrophysiological feature is a conduction block. Additionally, pure motor and sensory CIDP variants have been documented, with some cases restricted to sensory nerve roots, referred to as chronic immune sensory polyradiculopathy. CIDP is diagnosed based on electrodiagnostic or pathological evidence of demyelination and a positive response to immunomodulatory therapies. The most common subtype is typical CIDP, accounting for at least 50 to 60 percent of all cases. Panzyga® (Immune Globulin Intravenous [Human] – 10 percent Liquid Preparation) treats adults with CIDP, a neurological disorder affecting the peripheral nerves.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034